Centre Told To Decide On Cancer Drug At Low Price

KOCHI : The Kerala High Court on Tuesday directed the Union government to decide within one month whether it could intervene and make available a lifesaving medicine for breast cancer patients in the country at an affordable price.

“As per the available statistics, an alarming number of women succumb to breast cancer by reason of their inability to afford expensive treatment and medication. The right to life guaranteed under the Constitution, coupled with the State’s duty to improve public health, calls for emergent and effective action in the matter,” held the court.

The court was hearing a petition filed by a retired bank employee, diagnosed with HER2- Negative Metastatic Breast Cancer and is undergoing ‘targeted therapy’ treatment. The petitioner said she is receiving a monthly pension of ₹ 28,000 and the monthly cost of the medicines for her treatment comes to ₹63,480. One medicine, Ribociclib, alone costs ₹ 58,140 per month, she said.

Ribociclib is an imported medicine and if it’s manufactured in Inida the cost will come down substantially, the petitioner submitted.  Ribociclib presently enjoys a patent monopoly and its manufacturers are hence prevented from producing the medicine without the consent of the patent holder.

Section 92 of the Patents Act, 1970 provides for compulsory license and section 100 empowers the government to requisition lifesaving medicines in cases of extreme necessity, the petitioner said. Citing these, she had submitted a representation before various authorities requesting immediate action. She had received an acknowledgement from the Ministry of Women and Child Development that informed her that the representation is now before the Department for Promotion of Industry and Internal Trade (DPIIT).

  • Related Posts

    HP HC quashes CDSCO complaints against pharma firms over jurisdictional and procedural lapses

    In a landmark ruling that will have far-reaching implications for the pharmaceutical sector, the High Court of Himachal Pradesh has quashed three criminal complaints filed by the Central Drugs Standard…

    Eli Lilly launches cancer drug Tanstrive in India

    New Delhi: Eli Lilly and Company India on Thursday announced the launch of its cancer treatment drug Tanstrive in India. The launch follows marketing authorisation from the Central Drugs Standard Control Organisation…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    HP HC quashes CDSCO complaints against pharma firms over jurisdictional and procedural lapses

    HP HC quashes CDSCO complaints against pharma firms over jurisdictional and procedural lapses

    Eli Lilly launches cancer drug Tanstrive in India

    Eli Lilly launches cancer drug Tanstrive in India

    Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

    Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

    Centre eases BIS quality compliance with new risk-based framework for manufacturers

    Centre eases BIS quality compliance with new risk-based framework for manufacturers

    SS Innovations International aces Race beating Global Giants in Surgical Robotics

    SS Innovations International aces Race beating Global Giants in Surgical Robotics

    ‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility

    ‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility